Agonist and antagonist binding to alpha 2-adrenergic receptors in purified membranes from human platelets. Implications of receptor- inhibitory nucleotide-binding protein stoichiometry

RR Neubig, RD Gantzos and RS Brasier

The agonist- and antagonist-binding properties of the alpha 2- adrenergic receptor in a purified plasma membrane preparation from human platelets were determined both by direct binding of radiolabeled ligands and by competition with the labeled alpha 2-antagonist, [3H] yohimbine. Binding of [3H]yohimbine was characterized by a single high affinity binding site (Kd = 6.2 +/- 1.4 nM, Bmax = 507 +/- 53 fmol/mg). In direct binding studies, the imidazoline full alpha 2-agonist, [3H]-5- bromo-6-N(2-4,5-dihydroimidazolyl)quinoxaline ([3H] UK 14,304), bound to only one quantifiable high affinity site (Kd = 0.88 +/- 0.17 nM), representing 65 +/- 6% of the number of [3H]yohimbine sites. Binding of the partial agonist [3H]-p-aminoclonidine (PAC) showed nonlinear Scatchard plots. Analysis according to a model of multiple independent binding sites showed the data to be consistent with two sites (Kd1 = 0.62 +/- 0.18 nM and Kd2 = 7.9 +/- 1.4 nM). The high affinity site corresponded to 15 +/- 6% and the low affinity site corresponded to 39 +/- 6% of the number of [3H]yohimbine sites. Competition for binding of the alpha 2-antagonist, [3H]yohimbine, with nonradiolabeled ligands revealed a single affinity for yohimbine. In contrast, competition for [3H]yohimbine binding by the full agonist UK 14,304 and epinephrine is best fit by a model with two independent binding sites. The partial agonist PAC was best characterized by a model with three distinct binding sites. The full agonists UK 14,304 and epinephrine inhibited adenylate cyclase approximately 30%, whereas PAC produced only 12% inhibition. The inhibitory guanine nucleotide-binding protein (Ni) with Mr 40,700 was the sole pertussis toxin substrate in the purified membranes. It was quantitated by pertussis toxin-catalyzed [32P]ADP ribosylation in cholate extracts. There is a 20- to 100-fold excess of Ni over alpha 2-adrenergic receptors. Comparisons made between the experimental data for agonist binding and theoretical predictions of the simple ternary complex model suggest that there is compartmentalization of Ni and/or that the alpha 2 receptors are heterogeneous.

Volume 28, Issue 5, pp. 475-486, 11/01/1985
Copyright © 1985 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				Y. Kurachi and M. Ishii Cell signal control of the G protein-gated potassium channel and its subcellular localization J. Physiol., January 15, 2004; 554(2): 285 - 294. [Abstract] [Full Text] [PDF]

				S. M. Wade, K.-L. Lan, D. J. Moore, and R. R. Neubig Inverse Agonist Activity at the {alpha}2A-Adrenergic Receptor Mol. Pharmacol., March 1, 2001; 59(3): 532 - 542. [Abstract] [Full Text]

				P. C. Dunlop, L. A. Leis, and G. J. Johnson Epinephrine correction of impaired platelet thromboxane receptor signaling Am J Physiol Cell Physiol, December 1, 2000; 279(6): C1760 - C1771. [Abstract] [Full Text] [PDF]

				S. M. Wade, W. K. Lim, K.-L. Lan, D. A. Chung, M. Nanamori, and R. R. Neubig Gi Activator Region of alpha 2A-Adrenergic Receptors: Distinct Basic Residues Mediate Gi versus Gs Activation Mol. Pharmacol., November 1, 1999; 56(5): 1005 - 1013. [Abstract] [Full Text]

				S. R. J. Hoare, G. de Vries, and T. B. Usdin Measurement of Agonist and Antagonist Ligand-Binding Parameters at the Human Parathyroid Hormone Type 1 Receptor: Evaluation of Receptor States and Modulation by Guanine Nucleotide J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1323 - 1333. [Abstract] [Full Text]

				M. A. Supiano, R. V. Hogikyan, M. A. Sidani, A. T. Galecki, and J. L. Krueger Sympathetic nervous system activity and alpha -adrenergic responsiveness in older hypertensive humans Am J Physiol Endocrinol Metab, March 1, 1999; 276(3): E519 - E528. [Abstract] [Full Text] [PDF]